Clinical Trials: A clinical trial involves research participants. It follows a pre-defined plan or protocol to evaluate the effects of a medical or behavioral intervention on health outcomes. Clinical trials are done to determine whether new drugs or treatments are safe and effective. By taking part in clinical trials, participants not only play a more active role in their own health care, but they also can access experimental treatments and help others by contributing to medical research.
Drug overdose surpassed motor vehicle accidents as the leading cause of accidental death 2006 and has remained the leading cause of accidental death at the state and national level. Mos...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present a lung cancer case study to show how QIAG...
The main problem for insufficient cervical cancer screening globally (less than 20% women at risk) is outreach failure. Enabling POCs with modern IT/mobile technology and connecting them with...
Cervical cancer is the 4th most common cancer worldwide with 528,000 new cases and 266,000 deaths every year. It is also the only cancer 100% preventable. It has been extensively proved, that...
Clinical testing with next generation sequencing requires a complex bioinformatics pipeline to process raw DNA sequence into interpretable variants for medical reporting. With sequencin...
Point-of-care testing (POCT) allows for prompt clinical interventions by returning fast and reliable results near patients. This important role in patient management has led to the widespread...
This presentation will review the scope and history of the chronic pain and opioid epidemic in the US. It will then discuss how chronic pain and opioid use is being dealt with in commun...
In contrast to autologous cell therapies, allogeneic therapies do not require collection of starting material from patients and could; be manufactured in larger batches, be made available &ld...
Second and third generations of PTH immunoassays currently available on the market demonstrate significant variability with up to 4.2 fold difference in measurements depending on the method u...
As the compendium of putatively disease causing variants expands, gathering the most current and accurate information is critical to computing variant classifications. The QIAGEN knowledgebas...
Decades of innovation have brought us into a new era of mass spectrometry with the design of Agilent’s revolutionary Triple Quadrupole LC/MS. Ultivo is packed full of the same power and...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
As the diagnostic test menu has increased in size and complexity, healthcare providers are in great need of advice on appropriate test selection and result interpretation. To address this nee...
Sepsis is the Achilles’ heel of health care. Despite being relatively unknown to the public, it is a top killer in hospitals and the cost burden is crushing to our healthcare system. Mo...
DATE: November 9, 2018 TIME: 09:00am CST, 10:00am JST, 12:00pm AEDT Perso and precision medicine are rapidly growing areas that require good data to categoriz...
The D-dimer can be a useful tool in the management of patients with suspected or established venous thromboembolism (VTE). One use is in the assessment of a patient who presents with symptoms...
As the most common female malignancy, breast cancer is the most likely reason that a woman will die of cancer around the world. Breast cancer mortality has dropped in the U.S. by 35% since 19...
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
High dose of biotin may interference with many routine clinical immunoassays and inaccurate results of some of the tests such as cardiac troponin has serious clinical complications. There is...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
In the past two decades a small number of infrequently dividing cells have been proposed as the source of multi-drug resistance during cancer treatment. These cells identified by their expres...
PacBio Sequencing simultaneously provides long sequence reads, high consensus accuracy, minimal sequence bias, and methylation detection. I will highlight new advances and updates on applying...
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...
Drug overdose surpassed motor vehicle accidents as the leading cause of accidental death 2006 and has remained the leading cause of accidental death at the state and national level. Mos...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present a lung cancer case study to show how QIAG...
The main problem for insufficient cervical cancer screening globally (less than 20% women at risk) is outreach failure. Enabling POCs with modern IT/mobile technology and connecting them with...
Cervical cancer is the 4th most common cancer worldwide with 528,000 new cases and 266,000 deaths every year. It is also the only cancer 100% preventable. It has been extensively proved, that...
Clinical testing with next generation sequencing requires a complex bioinformatics pipeline to process raw DNA sequence into interpretable variants for medical reporting. With sequencin...
Point-of-care testing (POCT) allows for prompt clinical interventions by returning fast and reliable results near patients. This important role in patient management has led to the widespread...
This presentation will review the scope and history of the chronic pain and opioid epidemic in the US. It will then discuss how chronic pain and opioid use is being dealt with in commun...
In contrast to autologous cell therapies, allogeneic therapies do not require collection of starting material from patients and could; be manufactured in larger batches, be made available &ld...
Second and third generations of PTH immunoassays currently available on the market demonstrate significant variability with up to 4.2 fold difference in measurements depending on the method u...
As the compendium of putatively disease causing variants expands, gathering the most current and accurate information is critical to computing variant classifications. The QIAGEN knowledgebas...
Decades of innovation have brought us into a new era of mass spectrometry with the design of Agilent’s revolutionary Triple Quadrupole LC/MS. Ultivo is packed full of the same power and...
With significant decrease in the cost of sequencing in numerous commercial as well as cancer center–driven initiatives, genomic profiling is increasingly becoming routine across multipl...
As the diagnostic test menu has increased in size and complexity, healthcare providers are in great need of advice on appropriate test selection and result interpretation. To address this nee...
Sepsis is the Achilles’ heel of health care. Despite being relatively unknown to the public, it is a top killer in hospitals and the cost burden is crushing to our healthcare system. Mo...
DATE: November 9, 2018 TIME: 09:00am CST, 10:00am JST, 12:00pm AEDT Perso and precision medicine are rapidly growing areas that require good data to categoriz...
The D-dimer can be a useful tool in the management of patients with suspected or established venous thromboembolism (VTE). One use is in the assessment of a patient who presents with symptoms...
As the most common female malignancy, breast cancer is the most likely reason that a woman will die of cancer around the world. Breast cancer mortality has dropped in the U.S. by 35% since 19...
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
High dose of biotin may interference with many routine clinical immunoassays and inaccurate results of some of the tests such as cardiac troponin has serious clinical complications. There is...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
In the past two decades a small number of infrequently dividing cells have been proposed as the source of multi-drug resistance during cancer treatment. These cells identified by their expres...
PacBio Sequencing simultaneously provides long sequence reads, high consensus accuracy, minimal sequence bias, and methylation detection. I will highlight new advances and updates on applying...
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...
Follow
